| 47.55 0.82 (1.75%) | 07-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 66.27  |
1-year : | 74.1 |
| Resists | First : | 56.74 |
Second : | 63.45 |
| Pivot price | 49.89 |
|||
| Supports | First : | 45.88 |
Second : | 38.18 |
| MAs | MA(5) : | 47.11 |
MA(20) : | 52.06 |
| MA(100) : | 51.92 |
MA(250) : | 55.23 |
|
| MACD | MACD : | -2 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 4.9 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 78.48 | Low : | 44.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRSP ] has closed above bottom band by 34.0%. Bollinger Bands are 24.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 48.06 - 48.26 | 48.26 - 48.44 |
| Low: | 45.42 - 45.63 | 45.63 - 45.83 |
| Close: | 47.21 - 47.54 | 47.54 - 47.86 |
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Tue, 28 Jul 2026
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Tue, 28 Jul 2026
CRSP|CRISPR Therapeutics AG|Price:46.770|Chg%:+0.230 - TradingKey
Mon, 27 Jul 2026
BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics - Stock Titan
Mon, 27 Jul 2026
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Sun, 26 Jul 2026
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Sat, 25 Jul 2026
Affinity Asset Advisors LLC Buys Shares of 150,000 CRISPR Therapeutics AG $CRSP - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 9.604e+007 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 26,570 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.3108e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 933.3 % |
| Return on Equity (ttm) | -14.1 % |
| Qtrly Rev. Growth | 4.1e+006 % |
| Gross Profit (p.s.) | 40.35 |
| Sales Per Share | -18.36 |
| EBITDA (p.s.) | -2.81594e+008 |
| Qtrly Earnings Growth | -6.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -400 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.6 |
| Price to Cash Flow | 4.29 |
| Dividend | 0 |
| Forward Dividend | 1.981e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|